AIM ImmunoTech (AIM) Price & Analysis

Compare

925 Followers

AIM Stock Chart & Stats

$1.35

>-$0.01(-4.03%)

At close: Jan 08 4:00 PM EST

$1.35

>-$0.01(-4.03%)

Day’s Range― - ―

52-Week Range$1.26 - $36.27

Previous CloseN/A

Volume272.06K

Average Volume (3M)62.53K

Market Cap

$3.94M

Enterprise Value$5.67M

Total Cash (Recent Filing)$2.41M

Total Debt (Recent Filing)$2.34M

Price to Earnings (P/E)―

Beta1.56

Next Earnings

Apr 07, 2026

EPS Estimate

-0.94

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.57

Shares Outstanding2,938,681

10 Day Avg. Volume68,321

30 Day Avg. Volume62,527

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)-8.47

Price to Sales (P/S)65.90

P/FCF Ratio-0.75

Enterprise Value/Market Cap1.44

Enterprise Value/Revenue50.58

Enterprise Value/Gross Profit269.76

Enterprise Value/Ebitda-0.38

Forecast

1Y Price Target

$24.00

Price Target Upside1677.78% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-7.29

Revenue Forecast (FY)$100.00K

Bulls Say, Bears Say

Bulls Say

Analyst RatingThe analyst maintains a BUY rating for AIM, seeing large upside opportunities that balance high risks with high growth prospects.

Clinical TrialsPositive data from a Phase 2 study for Ampligen as a therapeutic for patients with post-COVID conditions could boost stock performance.

Bears Say

Corporate GovernanceDissident stockholders have nominated their own slate of directors for the third consecutive year, indicating potential ongoing governance challenges.

Stock ListingThe company's stock has been delisted from NYSE American and is now trading on Pink Open Market, which might impact investor confidence.

AIM ImmunoTech News

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

2d ago

AIM

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

3d ago

AIM

RADX

AIM ImmunoTech Completes 2025 Annual Stockholder Meeting

An update from AIM ImmunoTech ( ($AIM) ) is now available. On December 16, 2025, AIM ImmunoTech held...

3d ago

AIM

AIM ImmunoTech Enters Note Purchase Agreement

AIM ImmunoTech ( ($AIM) ) has shared an update. On November 18, 2025, AIM ImmunoTech Inc. entered into...

1M ago

AIM

AIM ImmunoTech reports Q3 EPS ($1.57) vs ($6.00) last year

“The third quarter was marked by solid and positive clinical and operational execution. Our clinical, manufacturing and regulatory...

1M ago

AIM

AIM ImmunoTech Reports Q3 2025 Financial Results

Aim Immunotech Inc. ( ($AIM) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

AIM

AIM ImmunoTech Delays Q3 2025 Report Filing

AIM ImmunoTech ( ($AIM) ) has released a notification of late filing. AIM ImmunoTech has announced a delay...

1M ago

AIM

AIM Upcoming Earnings Report: What to Expect?

Aim Immunotech Inc. (AIM) is scheduled to report 3rd quarter earnings on 11/14/2025. Regarding Q3 estimates, Wall Street...

1M ago

AIM

AIM ImmunoTech details UPMC abstract on completed Ampligen trial

AIM ImmunoTech (AIM) detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer...

1M ago

AIM

AIM ImmunoTech announces grant of European patent covering Ampligen

AIM ImmunoTech (AIM) announced that the European Patent Office has officially granted AIM’s European Patent No. 4,096,675, titled...

2M ago

AIM

AIM ImmunoTech Updates Certificate of Incorporation

AIM ImmunoTech ( ($AIM) ) has issued an announcement. AIM ImmunoTech has filed an amended and restated Certificate...

2M ago

AIM

AIM ImmunoTech Presents at Maxim Growth Summit 2025

An update from AIM ImmunoTech ( ($AIM) ) is now available. AIM ImmunoTech announced its participation in the...

2M ago

AIM

AIM ImmunoTech presents Phase 1a trial data for faridoxorubicin

Avacta Therapeutics announces further development updates in the Phase 1a clinical trial with its lead program, faridoxorubicin to...

2M ago

AIM

AIM ImmunoTech secures patent in Japan through 2039 for therapy using Ampligen

AIM ImmunoTech (AIM) announced that the Japan Patent Office has issued a patent covering the Company’s proprietary use...

3M ago

AIM

AIM FAQ

What was Aim Immunotech Inc.’s price range in the past 12 months?

Aim Immunotech Inc. lowest stock price was $1.26 and its highest was $36.27 in the past 12 months.

What is Aim Immunotech Inc.’s market cap?

Aim Immunotech Inc.’s market cap is $3.94M.

When is Aim Immunotech Inc.’s upcoming earnings report date?

Aim Immunotech Inc.’s upcoming earnings report date is Apr 07, 2026 which is in 107 days.

How were Aim Immunotech Inc.’s earnings last quarter?

Aim Immunotech Inc. released its earnings results on Nov 18, 2025. The company reported -$1.57 earnings per share for the quarter, missing the consensus estimate of -$0.975 by -$0.595.

Is Aim Immunotech Inc. overvalued?

According to Wall Street analysts Aim Immunotech Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aim Immunotech Inc. pay dividends?

Aim Immunotech Inc. pays a N/A dividend of $0.272 which represents an annual dividend yield of N/A. See more information on Aim Immunotech Inc. dividends here

What is Aim Immunotech Inc.’s EPS estimate?

Aim Immunotech Inc.’s EPS estimate is -0.94.

How many shares outstanding does Aim Immunotech Inc. have?

Aim Immunotech Inc. has 2,938,681 shares outstanding.

What happened to Aim Immunotech Inc.’s price movement after its last earnings report?

Aim Immunotech Inc. reported an EPS of -$1.57 in its last earnings report, missing expectations of -$0.975. Following the earnings report the stock price went down -7.639%.

Which hedge fund is a major shareholder of Aim Immunotech Inc.?

Currently, no hedge funds are holding shares in AIM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Aim Immunotech Inc.

AIM ImmunoTech Inc. is a biotechnology company focused on developing and commercializing novel immunotherapy products for the treatment of various diseases, including cancer and viral infections. The company's core product, Ampligen, is an experimental drug that acts as a therapeutic agent by enhancing the immune response. AIM operates primarily in the biotechnology and pharmaceutical sectors, with a commitment to advancing innovative therapies that harness the body's immune system to fight diseases.

AIM ImmunoTech (AIM) Earnings & Revenues

Historic Earnings Reports

AIM Stock 12 Month Forecast

Average Price Target

$24.00

▲(1677.78% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","50":"$50","13.25":"$13.25","25.5":"$25.5","37.75":"$37.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,13.25,25.5,37.75,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,3.7846153846153845,5.469230769230769,7.153846153846153,8.838461538461537,10.523076923076921,12.207692307692307,13.892307692307691,15.576923076923075,17.26153846153846,18.946153846153845,20.63076923076923,22.315384615384616,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,3.7846153846153845,5.469230769230769,7.153846153846153,8.838461538461537,10.523076923076921,12.207692307692307,13.892307692307691,15.576923076923075,17.26153846153846,18.946153846153845,20.63076923076923,22.315384615384616,{"y":24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.1,3.7846153846153845,5.469230769230769,7.153846153846153,8.838461538461537,10.523076923076921,12.207692307692307,13.892307692307691,15.576923076923075,17.26153846153846,18.946153846153845,20.63076923076923,22.315384615384616,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":49.01,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.11,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.8,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >